Syphilis and gonorrhoea diagnoses see significant increase

Syphilis and gonorrhoea diagnoses see significant increase

June 11 2018 Annual reporting of sexually transmitted infection diagnoses has increased 0.3% in...

Anticholinergics linked to increased risk of dementia

Anticholinergics linked to increased risk of dementia

April 30 2018 Anticholinergic drugs used in helping control some involuntary muscle movement...

Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

April 26 2018 Women and girls of childbearing potential must no longer take valproate medicines...

Buprenorphine may be safer than methadone in opioid substitute therapy, study suggests

Buprenorphine may be safer than methadone in opioid substitute therapy, study suggests

April 23 2018 Buprenorphine has been found to have lower rates of overdose death than methadone...

Class of diabetes drug linked to increased risk of irritable bowel disease

Class of diabetes drug linked to increased risk of irritable bowel disease

March 29 2018 A study has shown that dipeptidylpeptidase-4 inhibitors may increase the risk of...

  • Syphilis and gonorrhoea diagnoses see significant increase

    Syphilis and gonorrhoea diagnoses see significant increase

    Monday, 11 June 2018 14:16
  • Anticholinergics linked to increased risk of dementia

    Anticholinergics linked to increased risk of dementia

    Monday, 30 April 2018 12:08
  • Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

    Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

    Thursday, 26 April 2018 11:48
  • Buprenorphine may be safer than methadone in opioid substitute therapy, study suggests

    Buprenorphine may be safer than methadone in opioid substitute therapy, study suggests

    Monday, 23 April 2018 16:48
  • Class of diabetes drug linked to increased risk of irritable bowel disease

    Class of diabetes drug linked to increased risk of irritable bowel disease

    Thursday, 29 March 2018 11:27

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

diabetes4April 20 2016

Patients taking sodium-glucose co-transporter 2 (SGLT2) inhibitors (canagliflozin, dapagliflozin, or empagliflozin) need to be told about diabetic ketoacidosis, the medicines regulator has said.

Patients taking the drugs to improve glycaemic control in diabetes should be informed about the signs and symptoms of diabetic ketoacidosis (DKA), and advised to seek immediate medical advice if they develop them.

In addition, health professionals should:

  • discuss the risk factors for DKA with patients;
  • discontinue treatment with the SGLT2 inhibitor immediately if DKA is suspected or diagnosed;
  • not restart treatment with any SGLT2 inhibitor in patients who experienced DKA during use, unless another cause for DKA was identified and resolved;
  • interrupt treatment with the SGLT2 inhibitor in patients who are hospitalised for major surgery or acute serious illnesses; treatment may be restarted once the patient’s condition has stabilised;
  • report suspected side effects to SGLT2 inhibitors or any other medicines on a Yellow Card.

The advice was issued following reviews of the side effect, which is considered rare: by the end of February, the MHRA has received 118 yellow Card reports of DKA in association with an SGLT2 inhibitor. While SGLT2 inhibitors are indicated for type 2 diabetes, a number of DKA cases have been reported where the use was off-label in type 1 diabetes.

“In several cases, blood glucose levels were only moderately elevated (eg <14mmol/L)—representing an atypical presentation for DKA, which could delay diagnosis and treatment,” noted the MHRA.

“Therefore inform patients of the signs and symptoms of DKA (eg rapid weight loss, feeling sick or being sick, stomach pain, fast and deep breathing, sleepiness, a sweet smell to the breath, a sweet or metallic taste in the mouth, or a different odour to urine or sweat) and test for raised ketones in patients with these signs and symptoms.”

The advisory is one of a number of Drug Safety Updates issued by the medicines regulator, the MHRA, this week.

A second DSU gave advice around minimising the risk of cardiac side effects for patients taking apomorphine concomitantly with domperidone, saying patients should be monitored regularly and be aware of changes that could increase arrhythmia risk.

These include:

  • symptoms of cardiac or hepatic disorder
  • changes to electrolyte levels, such as due to diarrhoea or starting a diuretic
  • starting any other medicines

Another DSU has highlighted the fire risk of smoking or using a naked flame when a patient is using paraffin-based skin emollients. “We are aware of a recent fatal incident reported to the NHS England National Reporting and Learning System, in which a naked flame ignited emollient in contact with a patient’s dressings and clothing,” said the MHRA.

Among the other DSU advisories were that as meprobamate is being withdrawn from the market at the end of 2016, prescribers should be reviewing patients being treated with meprabomate for anxiety states or musculoskeletal disorders. Existing patients should be switched to an alternative, and no new patients should be started on meprobamate.

Links:

MHRA Drug Safety Updates

MHRA SGLT2 diabetic ketoacidosis warning

MHRA apomorphine domperidone warning

MHRA paraffin emollients

MHRA meprobomate advisory

Clinical News

June 22 2018 A review into the scheduling of cannabis for medicinal purposes will look for “significant medical and therapeutic benefits” before a decision is made.
June 19 2018 A practice-based audit will seek to explore community pharmacy’s contribution in supporting girls and women of childbearing potential who need to take valproate medicines. Launched by...